CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on stomach cancer shows early promise
Disease control Recruiting nowThis early-phase trial tests two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be surgically removed. Pembrolizumab helps the immune system fight cancer, while lenvatinib blocks enzymes that help …
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:32 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug targets Hard-to-Treat cancers with specific mutations
Disease control Recruiting nowThis study tests a drug called avapritinib in people with advanced solid tumors that have spread and have specific gene changes (CKIT or PDGFRA mutations). The drug works by blocking enzymes that help cancer cells grow. The goal is to see if avapritinib can shrink or control thes…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New radiation method could spare heart and lungs in esophageal cancer patients
Disease control Recruiting nowThis study compares two radiation techniques for people with stage I to IVA esophageal cancer: proton beam therapy (PBT) and intensity modulated photon radiotherapy (IMRT). The goal is to see which one helps patients live longer and causes fewer serious heart and lung side effect…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 11, 2026 20:50 UTC